FREMONT, Calif., May 18, 2011 /PRNewswire/ -- Biomerix Corporation and Cellon today announced a strategic distribution agreement for the Biomerix 3D Scaffold, a novel three-dimensional tissue scaffold. Under the agreement, Cellon will market and distribute the Biomerix 3D Scaffold to research institutions across Europe.
Comprised of a non-degradable, three-dimensional, open-cell polycarbonate polyurethane, the Biomerix 3D Scaffold is designed to mimic the nature and function of the extracellular matrix (ECM). Its novel macroporous microarchitecture consists of a network of interconnecting cells and pores, creating an environment highly conducive to applications in regenerative medicine, drug discovery, and stem cell research. The unique chemistry and microarchitecture of the Biomerix 3D Scaffold has been demonstrated to support optimal cell proliferation and superior cell viability in both in-vitro and in-vivo studies involving diverse cell types, including hematopoetic stem cells, mesenchymal stem cells, induced pluripotent stem cells, human adipose stem cells, human osteoblasts, fibroblasts, and fibrochondrocytes.
"Biomerix is delighted to form this new strategic partnership with Cellon, further strengthening each company's European presence in the field of regenerative medicine, tissue engineering, and drug discovery, development and delivery. The proprietary Biomerix Biomaterial used to manufacture the Biomerix 3D Scaffold has received seven US and international regulatory clearances for different indications in soft tissue repair, orthopedics, and vascular embolization," said Kenneth Hayes, President and Chief Executive Officer of Biomerix Corporation.
About Biomerix Corporation
Biomerix Corporation is recognized as a leader in the development and manufacturing of innovative non-absorbable and bioresorbable three-dimensional, open-cell, resilient elastomeric polyurethane biomaterials. The Company's expertise includes the development, co-development and supply of new proprietary materials, products and components to customers in the medical, industrial and consumer industry markets.
For more information please visit www.biomerix.com or call 888.308.3620.
About Cellon S.A.
CELLON is a rapidly growing company, established in 1987 to provide products and services to the vaccine production and bioprocessing industries. Areas of expertise include mammalian cell culture processes and the storage & transport of sterile liquids. Our success to-date has been built upon an understanding of the requirements of this demanding business sector - which has led to the formation of many collaborative relationships with our customers. Such partnerships have enabled us to develop a range of products to meet specific industry needs - in unique, often revolutionary, ways.
For more information please visit www.cellon.lu.
SOURCE Biomerix Corporation